Suppr超能文献

脆弱双核阿米巴会引发腹泻吗?一项系统综述。

Does Dientamoeba fragilis cause diarrhea? A systematic review.

作者信息

Wong Zing-Wae, Faulder Kate, Robinson Joan L

机构信息

University of Alberta, Edmonton, AB, Canada.

, Edmonton, Canada.

出版信息

Parasitol Res. 2018 Apr;117(4):971-980. doi: 10.1007/s00436-018-5771-4. Epub 2018 Feb 5.

Abstract

It remains controversial whether Dientamoeba fragilis is a commensal parasite or a pathogen. The objective of this systematic review was to establish the strength of the evidence that Dientamoeba fragilis would cause diarrhea. A search was performed for studies that reported either the association between D. fragilis detection in stools and diarrhea or diarrhea outcomes with D. fragilis therapy or challenge. Data from seven studies of specific populations reported that 22% had D. fragilis in stools of which only 23% had diarrhea. Eleven studies of stool samples submitted to laboratories reported that 4.3% of individuals had D. fragilis of which 54% had diarrhea. Twelve studies reported that D. fragilis was detected from 1.6% of individuals with diarrhea and 9.6% of diarrheal stools. Five studies analyzed the prevalence of D. fragilis in individuals with and without diarrhea; the two with a statistically significant difference between groups had discordant results. The only cohort study with an appropriate control group reported diarrhea in a higher proportion of children with D. fragilis than in controls. No D. fragilis treatment studies included diarrhea as an outcome. There were only two challenge studies involving one person each. In conclusion, the evidence that D. fragilis would cause diarrhea or that treatment would hasten diarrhea resolution is inconclusive.

摘要

脆弱双核阿米巴是共生寄生虫还是病原体仍存在争议。本系统评价的目的是确定脆弱双核阿米巴会导致腹泻这一证据的强度。对报告粪便中脆弱双核阿米巴检测与腹泻之间的关联或脆弱双核阿米巴治疗或激发试验的腹泻结局的研究进行了检索。来自七项特定人群研究的数据报告称,22%的人粪便中有脆弱双核阿米巴,其中只有23%的人患有腹泻。提交给实验室的粪便样本的十一项研究报告称,4.3%的个体有脆弱双核阿米巴,其中54%的人患有腹泻。十二项研究报告称,在1.6%的腹泻患者和9.6%的腹泻粪便中检测到脆弱双核阿米巴。五项研究分析了有腹泻和无腹泻个体中脆弱双核阿米巴的患病率;两组之间有统计学显著差异的两项研究结果不一致。唯一一项有适当对照组的队列研究报告称,患有脆弱双核阿米巴的儿童腹泻比例高于对照组。没有脆弱双核阿米巴治疗研究将腹泻作为结局。只有两项激发试验,每项试验涉及一人。总之,脆弱双核阿米巴会导致腹泻或治疗会加速腹泻缓解的证据尚无定论。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验